Suven Life Sciences (Suven) will participate and present positive Preclinical and Phase-1 clinical data of advanced molecules from their portfolio of new chemical entities (NCEs) at Sleep 2018, A Joint Meeting of The American Academy of Sleep Medicine and The Sleep Research Society being held at Baltimore, MD, USA during June 2-6, 2018.
SLEEP is the premier world forum to present and discuss the latest developments in clinical sleep medicine and sleep and circadian science.
The SLEEP meeting provides evidence-based education to advance the science and clinical practice of sleep medicine, disseminates cutting-edge sleep and circadian research, promotes the translation of basic science into clinical practice.
During the conference Suven will present their Phase 2 ready differentiated Clinical stage therapeutic candidate SUVN-G3031 (Histamine-3 receptor antagonist) for the treatment of Narcolepsy and Narcolepsy associated with Cataplexy. Narcolepsy is a commercially attractive space with a large unmet need. The data presentation highlight Suven’s continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets.
